Lipella Pharmaceuticals Completes Enrollment in Phase 2a Trial of LP-310 for Oral Lichen Planus
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 08 2025
0mins
Should l Buy ?
Source: Newsfilter
Trial Enrollment Completion: Lipella Pharmaceuticals has completed enrollment for its Phase 2a trial of LP-310, an oral rinse treatment for oral lichen planus, across three dose cohorts at seven U.S. sites, with topline results expected in Q2 2025.
Next Steps and Significance: The trial aims to assess the safety and efficacy of LP-310, a non-steroidal treatment for a condition lacking FDA-approved therapies, with plans to submit an IND application for a Phase 2b trial by late 2025.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
